8-K: BIO-key Reports Reduced Net Loss Despite Revenue Dip in Q2 2024

BIO-key International reported a reduced net loss and improved cash flow from operations in Q2 2024, despite a decrease in revenue due to delayed software license recognition and lower project-related services revenue.

Summary

• BIO-key International announced its Q2 2024 financial results, showing a decrease in revenue to $1.1 million from $1.9 million in Q2 2023.
• The revenue decline was primarily due to a $450,000 delay in recognizing software license fees from its European subsidiary and a $200,000 decrease in project-related services revenue from a large customer.
• Despite the revenue drop, gross profit improved significantly to $0.9 million with a 77% gross margin, compared to $0.3 million and a 16.7% margin in Q2 2023, mainly due to a $1 million hardware reserve in the prior year.
• Operating expenses were reduced by $0.2 million compared to Q2 2023, reflecting cost management efforts.
• The company's net loss decreased to $1.7 million in Q2 2024 from $2.6 million in Q2 2023, primarily due to the hardware reserve in the previous year.
• Cash used in operating activities improved by 48%, decreasing to $1.1 million for the first six months of 2024 compared to $2.1 million in the same period of 2023.
• BIO-key had current assets of approximately $3.0 million, including $1.3 million in cash and cash equivalents, as of June 30, 2024.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive aspects like improved gross margin and reduced net loss, the significant revenue decline and ongoing losses temper the overall sentiment. The company is making progress in some areas but still faces significant challenges.

Positives

• Gross profit margin significantly increased to 77% in Q2 2024, up from 16.7% in Q2 2023.
• The company reduced its net loss by $0.9 million year-over-year in Q2.
• Cash used in operating activities improved by $1 million in the first six months of 2024 compared to the same period in 2023.
• BIO-key is seeing increased enterprise awareness of the importance of secure Identity and Access Management solutions.
• The company is building a growing base of high-margin annually recurring revenues.
• BIO-key continues to seek and implement cost reduction opportunities.
• BIO-key has expanded deployments with several key clients including the University of Iowa Hospital and Dayton Childrens Hospital.

Negatives

• Q2 2024 revenues decreased by $0.8 million compared to Q2 2023.
• The company experienced a delay in recognizing approximately $450,000 in software license fees.
• Project-related services revenue decreased by approximately $200,000 compared to the year-ago period for one large customer.
• The company reported a net loss of $1.7 million for Q2 2024.

Risks

• The company's performance is expected to remain variable on a quarter-to-quarter and year-over-year basis due to the timing of customer contracts.
• BIO-key has a history of losses and limited revenue.
• The company's ability to raise additional capital to satisfy working capital needs is a risk.
• There are risks related to the company's ability to protect its intellectual property.
• The company faces competition in the biometric technology industry.
• There are risks related to market acceptance of biometric products and the company's products under development.
• The company's ability to convert sales opportunities to customer contracts is a risk.
• The company's ability to expand into foreign markets is a risk.
• There are risks related to the integration of Swivel Secure into the business.
• Fluctuations in foreign currency exchange rates pose a risk.
• Delays in product development are a risk.
• The company faces commercial, reputational and regulatory risks due to the restatement of financial statements.
• The company's temporary loss of the use of a Registration Statement on Form S-3 to register securities in the future is a risk.
• The company's common stock could be delisted from the Nasdaq Capital Market if it fails to increase its stockholders equity to at least $2.5 million.
• There is a risk of disruption to the business if the company is unable to remediate certain material weaknesses in its internal controls over financial reporting.

Future Outlook

BIO-key remains focused on driving revenue growth and progressing the business to profitability and positive cash flow over the next several quarters. The company expects to benefit from the rollout and enforcement of increasingly stringent regulatory standards and cyber insurance underwriting requirements. They are also excited by the growth potential for their new Passkey:YOU solution.

Management Comments

• BIO-key CEO, Mike DePasquale, stated that Q2 was impacted by delays in closing software license contracts and lower non-recurring, project-related services revenue.
• He also mentioned that they remain encouraged by the growing enterprise awareness of the importance of implementing secure, zero-trust Identity and Access Management solutions.
• Management is focused on driving revenue growth and progressing the business to profitability and positive cash flow over the next several quarters.
• The company is working to support Channel Alliance Partners and progress larger-scale customer dialogues via direct sales efforts.
• Management believes BIO-key is well-positioned for the future.

Industry Context

The announcement highlights the growing demand for secure, zero-trust Identity and Access Management solutions, which is a key trend in the cybersecurity industry. BIO-key's focus on biometric authentication aligns with the increasing need for passwordless and multi-factor authentication solutions driven by regulatory standards and cyber insurance requirements. The introduction of Passkey:YOU positions the company to capitalize on the expanding deployment of passkey solutions.

Comparison to Industry Standards

• BIO-key's gross margin improvement to 77% is a positive sign, indicating better cost management and higher-margin revenue streams, however, this is largely due to a one off hardware reserve in the previous period.
• The company's revenue decline is a concern, as many competitors in the IAM space are experiencing growth due to increased demand for cybersecurity solutions.
• Companies like Okta and Ping Identity, which are larger players in the IAM market, have shown consistent revenue growth, while BIO-key is still working to achieve consistent growth.
• BIO-key's focus on biometric authentication is a differentiator, but it needs to demonstrate its ability to scale and compete with larger players offering a broader range of IAM solutions.
• The reduction in operating expenses is a positive step, but the company needs to continue to improve its financial performance to be competitive with industry leaders.

Stakeholder Impact

• Shareholders may be concerned about the revenue decline but encouraged by the improved gross margin and reduced net loss.
• Employees may be impacted by ongoing cost management initiatives.
• Customers may benefit from the company's new Passkey:YOU solution and expanded deployments.
• Suppliers may be affected by the company's financial performance.
• Creditors may be concerned about the company's ongoing losses.

Next Steps

• BIO-key will host an investor call on August 15th to discuss the results.
• The company will continue to focus on driving revenue growth and progressing the business to profitability and positive cash flow.
• BIO-key will work to support Channel Alliance Partners and progress larger-scale customer dialogues.
• The company will continue to seek and implement cost reduction opportunities.

Key Dates

Keywords

biometrics, identity and access management, IAM, authentication, cybersecurity, passwordless, multi-factor authentication, software license, gross margin, net loss, operating expenses, cash flow, FIDO Passkey